Alliancebernstein L.P. Castle Biosciences Inc Transaction History

Alliancebernstein L.P.

$275 Billion
Q1 2024

A detailed history of Alliancebernstein L.P. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 33,370 shares of CSTL stock, worth $726,464. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,370

Previous 44,690 25.33%

Holding current value

$726,464

Previous $964,000 23.34%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$18.06 - $25.3 $204,439 - $286,396	-11,320 Reduced 25.33%	33,370 $739,000
Q2 2023 Aug 15, 2023	BUY	$11.66 - $26.0 $258,735 - $576,940	22,190 Added 98.62%	44,690 $613,000
Q3 2022 Nov 15, 2022	SELL	$22.51 - $34.32 $476,896 - $727,103	-21,186 Reduced 48.5%	22,500 $587,000
Q2 2022 Aug 15, 2022	BUY	$16.0 - $45.99 $302,176 - $868,567	18,886 Added 76.15%	43,686 $959,000
Q1 2022 May 13, 2022	BUY	$33.17 - $46.98 $3,317 - $4,698	100 Added 0.4%	24,800 $1.11 Million

Q3 2021 Nov 10, 2021	SELL	$60.13 - $77.6 $36,078 - $46,560	-600 Reduced 2.37%	24,700 $1.64 Million
Q2 2021 Jul 30, 2021	BUY	$50.07 - $76.78 $610,854 - $936,716	12,200 Added 93.13%	25,300 $1.86 Million
Q1 2021 May 06, 2021	BUY	$58.92 - $97.33 $135,516 - $223,859	2,300 Added 21.3%	13,100 $897,000
Q4 2020 Feb 08, 2021	SELL	$43.6 - $73.05 $82,840 - $138,795	-1,900 Reduced 14.96%	10,800 $725,000
Q3 2020 Nov 12, 2020	SELL	$38.47 - $52.03 $30,776 - $41,624	-800 Reduced 5.93%	12,700 $653,000
Q2 2020 Aug 13, 2020	BUY	$27.28 - $43.01 $368,280 - $580,635	13,500 New	13,500 $509,000

Others Institutions Holding CSTL

# of Institutions

162

Shares Held

25.3M

Call Options Held

82.2K

Put Options Held

150K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $572M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Castle Biosciences Inc Transaction History